Skip to main content

Advertisement

Table 1 Baseline clinicopathologic and prognostic characteristics of 184 patients with metastatic renal cell carcinoma (mRCC)

From: Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma

Variable Total [cases (%)] Sorafenib group [cases (%)] Sunitinib group [cases (%)] P value
Total 184 110 74  
Sex     0.336
 Man 141 (76.6) 87 (84.3) 54 (73.0)  
 Woman 43 (23.4) 23 (25.7) 20 (27.0)  
Age (years)     0.152
 <65 139 (75.5) 79 (71.8) 60 (81.1)  
 ≥65 45 (24.5) 31 (28.2) 14 (18.9)  
Histology     0.872
 Clear cell 176 (95.7) 105 (95.5) 71 (96.0)  
 Others 8 (4.3) 5 (4.5) 3 (4.0)  
Prior nephrectomy     0.516
 Yes 150 (81.5) 88 (80.0) 62 (83.8)  
 No 34 (18.5) 22 (20.0) 12 (16.2)  
Prior cytokine therapy     0.118
 Yes 60 (32.6) 31 (28.2) 29 (39.2)  
 No 124 (67.4) 79 (71.8) 45 (60.8)  
Fuhrman grade     0.636
 1–2 106 (57.6) 64 (58.2) 42 (56.8)  
 3–4 64 (34.8) 35 (31.8) 29 (39.2)  
 Unknown 14 (7.6) 11 (10.0) 3 (4.0)  
Number of metastatic sites     0.084
 1 134 (72.8) 75 (68.2) 59 (79.7)  
 ≥2 50 (27.2) 35 (31.8) 15 (20.3)  
Metastatic sites
 Lung 139 (75.5) 81 (73.6) 58 (78.4) 0.463
 Lymph nodes 44 (23.9) 29 (26.4) 15 (20.3) 0.342
 Bone 19 (10.3) 12 (10.9) 7 (9.5) 0.751
 Liver 15 (8.2) 12 (10.9) 3 (4.1) 0.096
 Others 13 (7.1) 7 (6.4) 6 (8.1) 0.651
MSKCC grade     0.598
 Favorable 86 (46.7) 49 (44.6) 37 (50.0)  
 Intermediate 73 (39.7) 46 (41.8) 27 (36.5)  
 Poor 25 (13.6) 15 (13.6) 10 (13.5)  
IMDC risk     0.199
 Good 100 (54.3) 57 (51.8) 43 (58.1)  
 Intermediate 73 (39.7) 44 (40.0) 29 (39.2)  
 Poor 11 (6.0) 9 (8.2) 2 (2.7)  
  1. MSKCC Memorial Sloan-Kettering Cancer Center, IMDC International Metastatic Renal Cell Carcinoma Database Consortium